GT Molecular specializes in advanced molecular detection technologies, particularly in the fields of cancer research and pathogen detection. Their product offerings include high-performance PCR kits designed for various applications, such as cancer genotyping, pathogen testing, and wastewater surveillance. The company has developed ultra-sensitive digital PCR (dPCR) and real-time quantitative PCR (RT-qPCR) assays that can detect low concentrations of nucleic acids, enabling the identification of pathogens like SARS-CoV-2, Influenza, and RSV in wastewater samples. Their testing services promise rapid turnaround times, providing results within 24 to 48 hours after sample receipt, which is crucial for effective public health monitoring.

In addition to pathogen detection, GT Molecular offers multiplexed PCR panels for cancer research, allowing researchers to analyze multiple genetic mutations simultaneously. Their GT-Plex™ technology enhances assay efficiency by enabling the amplification of several targets in a single reaction, thus saving time and resources. The assays are designed to be user-friendly, including all necessary components such as primers, probes, and controls, and are validated for use with various digital PCR platforms. This comprehensive approach not only supports oncology research but also addresses regulatory needs in cannabis testing, ensuring the detection of common microbial contaminants in cannabis products.

United States

GT Molecular develops ultrasensitive Molecular Assays, Digital PCR and qPCR Tests End-to-End solutions for cancer detection and waterborne pathogens including SARS-CoV-2. Detect as little as 1-3 molecules of target DNA

GT Molecular

Company Details